Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.03)
# 3,327
Out of 4,413 analysts
28
Total ratings
4.55%
Success rate
-31.32%
Average return
Main Sectors:
Top Industries:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Initiates: Overweight | $82 | $43.98 | +86.45% | 1 | Apr 3, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $3.69 | - | 1 | Nov 8, 2023 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $56 → $32 | $21.74 | +47.19% | 9 | Oct 17, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $22 | $6.00 | +266.67% | 3 | Sep 13, 2023 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $22.50 | +188.89% | 4 | Sep 13, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $5.47 | +155.94% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $53.81 | +98.85% | 4 | Aug 8, 2022 |
Legend Biotech
Apr 3, 2024
Initiates: Overweight
Price Target: $82
Current: $43.98
Upside: +86.45%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $3.69
Upside: -
Beam Therapeutics
Oct 17, 2023
Maintains: Overweight
Price Target: $56 → $32
Current: $21.74
Upside: +47.19%
Verve Therapeutics
Sep 13, 2023
Reiterates: Neutral
Price Target: $22
Current: $6.00
Upside: +266.67%
Intellia Therapeutics
Sep 13, 2023
Reiterates: Overweight
Price Target: $65
Current: $22.50
Upside: +188.89%
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $5.47
Upside: +155.94%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $53.81
Upside: +98.85%